Trial Profile
A study of abiraterone and enzalutamide in AR-V7 positive, castration resistant prostate cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Aug 2016 New trial record